Cargando…
The Utility of Inflammatory Serum Markers in the Assessment of Perioperative Morbidity after Radical Cystectomy for Bladder Cancer
Background and Objectives: To date, sparse evidence exists about the impact of inflammatory serum markers in predicting perioperative complications after radical cystectomy (RC) for bladder cancer (BC). Here, we evaluated the role of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte r...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220654/ https://www.ncbi.nlm.nih.gov/pubmed/37241158 http://dx.doi.org/10.3390/medicina59050926 |
_version_ | 1785049269404696576 |
---|---|
author | Claps, Francesco Rossin, Giulio van Rhijn, Bas W. G. Mir, Maria Carmen Mertens, Laura S. Ongaro, Luca Traunero, Fabio Iachimovsky, Alexandra I. Piasentin, Andrea Vedovo, Francesca Perotti, Alessandro Tulone, Gabriele Zucchi, Alessandro Liguori, Giovanni Simonato, Alchiede Bartoletti, Riccardo Trombetta, Carlo Pavan, Nicola |
author_facet | Claps, Francesco Rossin, Giulio van Rhijn, Bas W. G. Mir, Maria Carmen Mertens, Laura S. Ongaro, Luca Traunero, Fabio Iachimovsky, Alexandra I. Piasentin, Andrea Vedovo, Francesca Perotti, Alessandro Tulone, Gabriele Zucchi, Alessandro Liguori, Giovanni Simonato, Alchiede Bartoletti, Riccardo Trombetta, Carlo Pavan, Nicola |
author_sort | Claps, Francesco |
collection | PubMed |
description | Background and Objectives: To date, sparse evidence exists about the impact of inflammatory serum markers in predicting perioperative complications after radical cystectomy (RC) for bladder cancer (BC). Here, we evaluated the role of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), C-reactive protein (CRP), and plasma fibrinogen in predicting perioperative morbidity and unplanned 30-days readmission after RC for BC. Materials and methods: We relied on a collaborative database of 271 patients who underwent open RC for cT1-4a N0 M0 BC between January 2012 and December 2022. Univariable and multivariable binomial logistic regression analyses were performed to assess the odds ratio (OR) with 95% confidence intervals (CI) testing the ability of each serum marker to predict postoperative complications (any-grade and major complications), and 30-days unplanned readmission. Results: The median age at RC was 73 yr (IQR 67–79). A total of 182 (67.2%) patients were male and the median BMI was 25.2 (IQR 23.2–28.4). Overall, 172 (63.5%) patients had a Charlson Comorbidity Index (CCI) greater than 2 points and 98 (36.2%) were current smokers at the time of RC. Overall, 233 (86.0%) patients experienced at least one complication after RC. Of these, 171 (63.1%) patients had minor complications (Clavien–Dindo grade 1–2) while 100 (36.9%) experienced major complications (Clavien–Dindo grade ≥ 3). According to multivariable analysis, current smoking status, high plasma fibrinogen, and preoperative anemia were independently associated with major complications (OR 2.10, 95%CI 1.15–4.90, p = 0.02), (OR 1.51, 95%CI 1.26–1.98, p = 0.09), and (OR 1.35, 95%CI 1.17–2.57, p = 0.03), respectively. Overall, 56 (20.7%) patients experienced a 30-days unplanned readmission. According to univariable analysis, high preoperative CRP and hyperfibrinogenemia were significantly associated with an increased risk of unplanned readmission (OR 2.15, 95%CI 1.15–4.16, p = 0.02; OR 2.18, 95%CI 1.13–4.44, p = 0.02, respectively). Conclusions: In our study, the preoperative immune-inflammation signature described by NLR, PLR, LMR, SII, and CRP showed a low reliability in predicting perioperative course after RC. Preoperative anemia and hyperfibrinogenemia were independent predictors of major complications. Further studies are pending in order to draw definitive conclusions. |
format | Online Article Text |
id | pubmed-10220654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102206542023-05-28 The Utility of Inflammatory Serum Markers in the Assessment of Perioperative Morbidity after Radical Cystectomy for Bladder Cancer Claps, Francesco Rossin, Giulio van Rhijn, Bas W. G. Mir, Maria Carmen Mertens, Laura S. Ongaro, Luca Traunero, Fabio Iachimovsky, Alexandra I. Piasentin, Andrea Vedovo, Francesca Perotti, Alessandro Tulone, Gabriele Zucchi, Alessandro Liguori, Giovanni Simonato, Alchiede Bartoletti, Riccardo Trombetta, Carlo Pavan, Nicola Medicina (Kaunas) Article Background and Objectives: To date, sparse evidence exists about the impact of inflammatory serum markers in predicting perioperative complications after radical cystectomy (RC) for bladder cancer (BC). Here, we evaluated the role of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), C-reactive protein (CRP), and plasma fibrinogen in predicting perioperative morbidity and unplanned 30-days readmission after RC for BC. Materials and methods: We relied on a collaborative database of 271 patients who underwent open RC for cT1-4a N0 M0 BC between January 2012 and December 2022. Univariable and multivariable binomial logistic regression analyses were performed to assess the odds ratio (OR) with 95% confidence intervals (CI) testing the ability of each serum marker to predict postoperative complications (any-grade and major complications), and 30-days unplanned readmission. Results: The median age at RC was 73 yr (IQR 67–79). A total of 182 (67.2%) patients were male and the median BMI was 25.2 (IQR 23.2–28.4). Overall, 172 (63.5%) patients had a Charlson Comorbidity Index (CCI) greater than 2 points and 98 (36.2%) were current smokers at the time of RC. Overall, 233 (86.0%) patients experienced at least one complication after RC. Of these, 171 (63.1%) patients had minor complications (Clavien–Dindo grade 1–2) while 100 (36.9%) experienced major complications (Clavien–Dindo grade ≥ 3). According to multivariable analysis, current smoking status, high plasma fibrinogen, and preoperative anemia were independently associated with major complications (OR 2.10, 95%CI 1.15–4.90, p = 0.02), (OR 1.51, 95%CI 1.26–1.98, p = 0.09), and (OR 1.35, 95%CI 1.17–2.57, p = 0.03), respectively. Overall, 56 (20.7%) patients experienced a 30-days unplanned readmission. According to univariable analysis, high preoperative CRP and hyperfibrinogenemia were significantly associated with an increased risk of unplanned readmission (OR 2.15, 95%CI 1.15–4.16, p = 0.02; OR 2.18, 95%CI 1.13–4.44, p = 0.02, respectively). Conclusions: In our study, the preoperative immune-inflammation signature described by NLR, PLR, LMR, SII, and CRP showed a low reliability in predicting perioperative course after RC. Preoperative anemia and hyperfibrinogenemia were independent predictors of major complications. Further studies are pending in order to draw definitive conclusions. MDPI 2023-05-11 /pmc/articles/PMC10220654/ /pubmed/37241158 http://dx.doi.org/10.3390/medicina59050926 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Claps, Francesco Rossin, Giulio van Rhijn, Bas W. G. Mir, Maria Carmen Mertens, Laura S. Ongaro, Luca Traunero, Fabio Iachimovsky, Alexandra I. Piasentin, Andrea Vedovo, Francesca Perotti, Alessandro Tulone, Gabriele Zucchi, Alessandro Liguori, Giovanni Simonato, Alchiede Bartoletti, Riccardo Trombetta, Carlo Pavan, Nicola The Utility of Inflammatory Serum Markers in the Assessment of Perioperative Morbidity after Radical Cystectomy for Bladder Cancer |
title | The Utility of Inflammatory Serum Markers in the Assessment of Perioperative Morbidity after Radical Cystectomy for Bladder Cancer |
title_full | The Utility of Inflammatory Serum Markers in the Assessment of Perioperative Morbidity after Radical Cystectomy for Bladder Cancer |
title_fullStr | The Utility of Inflammatory Serum Markers in the Assessment of Perioperative Morbidity after Radical Cystectomy for Bladder Cancer |
title_full_unstemmed | The Utility of Inflammatory Serum Markers in the Assessment of Perioperative Morbidity after Radical Cystectomy for Bladder Cancer |
title_short | The Utility of Inflammatory Serum Markers in the Assessment of Perioperative Morbidity after Radical Cystectomy for Bladder Cancer |
title_sort | utility of inflammatory serum markers in the assessment of perioperative morbidity after radical cystectomy for bladder cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220654/ https://www.ncbi.nlm.nih.gov/pubmed/37241158 http://dx.doi.org/10.3390/medicina59050926 |
work_keys_str_mv | AT clapsfrancesco theutilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT rossingiulio theutilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT vanrhijnbaswg theutilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT mirmariacarmen theutilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT mertenslauras theutilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT ongaroluca theutilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT traunerofabio theutilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT iachimovskyalexandrai theutilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT piasentinandrea theutilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT vedovofrancesca theutilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT perottialessandro theutilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT tulonegabriele theutilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT zucchialessandro theutilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT liguorigiovanni theutilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT simonatoalchiede theutilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT bartolettiriccardo theutilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT trombettacarlo theutilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT pavannicola theutilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT clapsfrancesco utilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT rossingiulio utilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT vanrhijnbaswg utilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT mirmariacarmen utilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT mertenslauras utilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT ongaroluca utilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT traunerofabio utilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT iachimovskyalexandrai utilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT piasentinandrea utilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT vedovofrancesca utilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT perottialessandro utilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT tulonegabriele utilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT zucchialessandro utilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT liguorigiovanni utilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT simonatoalchiede utilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT bartolettiriccardo utilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT trombettacarlo utilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer AT pavannicola utilityofinflammatoryserummarkersintheassessmentofperioperativemorbidityafterradicalcystectomyforbladdercancer |